Algert Global’s Minerva Neurosciences NERV Stock Holding History

Algert Global’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,916	Closed	-$120K	–	381
2019 Q1	$120K	Buy	+1,916	New	+$115K	0.07%	274

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Algert Global's NERV Position: Q2 2019 in Review

Algert Global sold out of Minerva Neurosciences (NERV) in Q2 2019, closing a stake of 1,916 shares — an estimated $120K sold.

Algert Global first reported a position in NERV in Q1 2019 and held it in 1 quarter. The position peaked at $120K in Q1 2019. 85 funds tracked by Wall St. Rank hold NERV as of Q2 2019.

Algert Global reported no remaining Minerva Neurosciences position as of Q2 2019 after selling out during the quarter.
Algert Global sold 1,916 Minerva Neurosciences shares in Q2 2019, an estimated $120K.
Algert Global first reported a position in Minerva Neurosciences in Q1 2019 and held it in 1 quarter.
Algert Global's Minerva Neurosciences position peaked at $120K in Q1 2019.
85 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2019.

Based on Algert Global's 13F filing for Q2 2019, filed 14 Aug 2019.